Literature DB >> 22122392

Clozapine safety, 35 years later.

Michele Raja1.   

Abstract

Clozapine is the best treatment option in several clinical circumstances, including treatment-resistant schizophrenia, non treatment-resistant schizophrenia, suicide risk in schizophrenia spectrum disorders, aggressiveness or violence in psychiatric patients, psychosis in Parkinson's disease, prevention and treatment of tardive dyskinesia. However, clozapine is associated with many serious side effects. Furthermore, monitoring requirements, i.e., frequent blood draws and frequent visits, discourage clozapine use. Therefore, the drug is underused. The only way to avoid the underuse of clozapine is full awareness of its side effects and competence to minimize them. The aim of the paper is reviewing the safety profile of clozapine and the suggested strategies in the management of its side effects, including neutropenia, eosinophilia, seizures, myocarditis, weight gain, diabetes, metabolic syndrome, hypersalivation, fever, constipation, ileus, urinary incontinence, sweating. The neuropsychiatric side effects of clozapine are not discussed in this review.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22122392     DOI: 10.2174/157488611797579230

Source DB:  PubMed          Journal:  Curr Drug Saf        ISSN: 1574-8863


  11 in total

Review 1.  Significant weight loss following clozapine use, how is it possible? A case report and review of published cases and literature relevant to the subject.

Authors:  Tongeji E Tungaraza
Journal:  Ther Adv Psychopharmacol       Date:  2016-05-31

2.  Japanese Society of Neuropsychopharmacology: "Guideline for Pharmacological Therapy of Schizophrenia".

Authors: 
Journal:  Neuropsychopharmacol Rep       Date:  2021-08-12

3.  Prevention of haloperidol-induced alterations in brain acetylcholinesterase activity by vitamins B co-administration in a rodent model of tardive dyskinesia.

Authors:  Gersilene Valente de Oliveira; Patrícia Xavier Lima Gomes; Fernanda Yvelize Ramos de Araújo; Silvânia Maria Mendes Vasconcelos; Hélio Vitoriano Nobre Júnior; Francisca Cléa Florenço de Sousa; David F de Lucena; Thomas N Hyphantis; André Férrer Carvalho; Danielle Silveira Macêdo
Journal:  Metab Brain Dis       Date:  2012-10-25       Impact factor: 3.584

4.  Clozapine prescribing in the UK: views and experience of consultant psychiatrists.

Authors:  Tongeji E Tungaraza; Saeed Farooq
Journal:  Ther Adv Psychopharmacol       Date:  2015-04

5.  Life-threatening haematemesis associated with clozapine: a case report and literature review.

Authors:  Kazeem Olaide Adebayo; Nurudeen Ibrahim; Temilola Mosanya; Benjamin Eegunranti; Babatunde Suleiman; Akeem Ayankunle
Journal:  Ther Adv Psychopharmacol       Date:  2013-10

Review 6.  Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold?

Authors:  Gary Remington; Ofer Agid; George Foussias; Larissa Ferguson; Krysta McDonald; Valerie Powell
Journal:  Psychopharmacology (Berl)       Date:  2012-11-22       Impact factor: 4.530

7.  Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications.

Authors:  Brian Godman; Max Petzold; Kathleen Bennett; Marion Bennie; Anna Bucsics; Alexander E Finlayson; Andrew Martin; Marie Persson; Jutta Piessnegger; Emanuel Raschi; Steven Simoens; Corinne Zara; Corrado Barbui
Journal:  BMC Med       Date:  2014-06-13       Impact factor: 8.775

8.  Clozapine response and pre-treatment EEG-is there some kind of relationship.

Authors:  Amresh Shrivastava; Megan Johnston; Nilesh Shah; Larry Stitt; Shivanshu Shrivastava; Avinash De Sousa
Journal:  Ind Psychiatry J       Date:  2014-01

9.  Psychiatric pharmacist's role in overcoming barriers to clozapine use and improving management.

Authors:  Deanna L Kelly; Raymond C Love
Journal:  Ment Health Clin       Date:  2019-03-01

10.  Potential to enhance the prescribing of generic drugs in patients with mental health problems in austria; implications for the future.

Authors:  Brian Godman; Anna Bucsics; Thomas Burkhardt; Jutta Piessnegger; Manuela Schmitzer; Corrado Barbui; Emanuel Raschi; Marion Bennie; Lars L Gustafsson
Journal:  Front Pharmacol       Date:  2013-01-07       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.